Teva (TEVA) Patent '413 on Capaxone Also Invalidated by U.S.

August 24, 2016 3:41 PM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

The U.S. Patent Office ruled that Teva Pharma's (NYSE: TEVA) patent '413 on Capaxone claims 1-20 are unpatentable. Earlier claims on its '250 patent were ruled unpatentable.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Hot Corp. News, Litigation, Trader Talk

Add Your Comment